Related Experiment Video

Updated: Apr 20, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.4K

A lack of association between the CRP rs2794520 polymorphism and coronary artery disease

Jiangfang Lian1, Junxing Li2, Dongjun Dai3

  • 1Ningbo Medical Center, Lihuili Hospital, School of Medicine, Ningbo University, Ningbo, Zhejiang 315000, P.R. China.

Biomedical Reports
|December 4, 2014
PubMed

Insights

The C-reactive protein (CRP) rs2794520 gene variant does not increase the risk of coronary artery disease (CAD). This study found no association between this CRP polymorphism and CAD development or severity.

Area of Science:

  • Cardiovascular Medicine
  • Genetics
  • Inflammation Biology

Background:

  • Coronary artery disease (CAD) is a leading cause of mortality, often linked to atherosclerosis.
  • C-reactive protein (CRP) is a key systemic inflammatory mediator implicated in cardiovascular disease.
  • Genetic variations in CRP may influence individual susceptibility to CAD.

Purpose of the Study:

  • To investigate the association between the CRP rs2794520 polymorphism and the risk of developing CAD.
  • To determine if the CRP rs2794520 polymorphism correlates with CAD severity.
  • To analyze potential gender or age-specific effects of the CRP rs2794520 polymorphism on CAD risk.

Main Methods:

  • A case-control study design was employed, recruiting 459 CAD patients and 432 non-CAD controls.
  • Genotyping of the CRP rs2794520 polymorphism was performed using the SEQUENOM Mass-ARRAY iPLEX platform.
  • Statistical analyses were conducted to assess the association between the polymorphism and CAD risk and severity.

Main Results:

  • The CRP rs2794520 polymorphism showed no statistically significant association with the overall risk of CAD.
  • Subgroup analyses based on age and gender did not reveal any link between the rs2794520 polymorphism and CAD.
  • No correlation was found between the CRP rs2794520 polymorphism and the severity of coronary artery stenosis.

Conclusions:

  • The CRP rs2794520 polymorphism does not appear to contribute to the risk of developing coronary artery disease.
  • This specific genetic variation in CRP is unlikely to be a significant factor in CAD pathogenesis or progression.
  • Further research may explore other genetic or environmental factors influencing CAD risk.

Keywords:
C-reactive proteincoronary artery diseaseno associationrs2794520

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.6K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.9K

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.7K
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
20.4K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
789
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
104
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
135
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
17.2K